EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy

Weiying Ou, Yaoyao Wang, Chengyu Hou, Shujuan Hou, Yumei Zhou, Ji Wang, Qi Wang

Frontiers in Immunology · 2026

DOI: 10.3389/fimmu.2026.1817893 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Weiying Ou und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Traditional Chinese Medicine (TCM) Constitution and Preventive Treatment of Disease, Wangqi Academy of Beijing University of Ch…. Hauptthemen laut MEDLINE: Interleukin-5, Eosinophils, Asthma, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophil-associated diseases are a group of inflammatory disorders characterized by abnormal eosinophil infiltration, which significantly impacts patients’ quality of life. Interleukin-5 (IL-5), a critical cytokine that regulates eosinophil development, activation, chemotaxis, and survival, plays a central role in the pathogenesis of these diseases. This review systematically examines the molecular structure and signaling pathways of IL-5, its mechanisms of action in asthma and chronic obstructive pulmonary disease (COPD), and the development and clinical applications of monoclonal antibodies (e.g., mepolizumab, benralizumab, reslizumab) and other biologics targeting IL-5. Although IL-5-targeted therapies have yielded significant results, single-target interventions still exhibit limitations, including insufficient responses in certain patients. To address this, we explore the strategy of multi-target combination therapies, such as the synergistic inhibition of IL-5 with the IL-4/IL-13 and IL-33/ST2 pathways. We also discuss the potential of novel therapeutic approaches, including bispecific antibodies and small-molecule inhibitors. Ultimately, multi-targeted precision therapies, tailored to individual inflammatory phenotypes, are anticipated to represent a new frontier in the management of eosinophil-associated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-5EosinophilsAsthmaPulmonary Disease, Chronic ObstructiveHumansAnimalsMolecular Targeted TherapySignal TransductionAntibodies, Monoclonal

Stichwörter der Autor:innen

biologicseosinophil-associated diseaseseosinophilsinterleukin-5multi-target therapy

Substanzen

Interleukin-5IL5 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • National Institute of Traditional Chinese Medicine (TCM) Constitution and Preventive Treatment of Disease, Wangqi Academy of Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • College of Traditional Chinese Medicine, Hubei University of Traditional Chinese Medicine, Wuhan, China.

Zitieren

APA

Ou, W., Wang, Y., Hou, C., Hou, S., Zhou, Y., Wang, J., & Wang, Q. (2026). Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1817893

Vancouver

Ou W, Wang Y, Hou C, Hou S, Zhou Y, Wang J, et al. Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1817893

BibTeX
@article{Ou2026,
  author = {Ou, Weiying and Wang, Yaoyao and Hou, Chengyu and Hou, Shujuan and Zhou, Yumei and Wang, Ji and Wang, Qi},
  title = {Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy},
  journal = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2026.1817893}
}
Kostenlos starten →